A group of family investment groups, along with institutional investors, has invested $150 million in a biotech company using AI and molecules found in nature to develop new therapeutics for the treatment of multiple diseases.
Subscribe
You will need a Premium+ Subscription to read this article.
Exclusive news, analysis and research on global family enterprise and private investment offices
Already have an account? Sign in
Already have an account? Sign in
You've reached the end.
Continue reading free articles by registering as a Member.
Or choose a Premium Plan.
Already have an account? Sign in